Physician profile
Greg Michael Thaera
NPI 1710199724
$3,264.80
in general payments reported to CMS, 2019-2025
36 companies · $794 in 2025
The $794 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $100 · 2020: $93.25 · 2021: $888 · 2022: $551 · 2023: $68.82 · 2024: $769 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,632.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $351.31 | 2021-2025 | |
| Amgen INC. | $281.71 | 2019-2022 | |
| Biogen, INC. | $243.33 | 2020-2025 | Tysabri, Skyclarys, Leqembi |
| Genentech USA, INC. | $204.37 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Novartis Pharmaceuticals Corporation | $200.49 | 2020-2025 | |
| Ucb, INC. | $197.72 | 2024-2025 | Rystiggo, Zilbrysq, Nayzilam |
| Genzyme Corporation | $190.78 | 2021-2022 | |
| Emd Serono, INC. | $171.43 | 2021-2025 | |
| Pfizer INC. | $167.42 | 2024-2025 | |
| Argenx US, INC. | $118.04 | 2024-2025 | Vyvgart Hytrulo |
| Acadia Pharmaceuticals INC | $102.74 | 2022-2025 | Nuplazid |
| Abbott Laboratories | $101.09 | 2019-2025 | Eterna, Jot Dx, Proclaim |
| Biohaven Pharmaceuticals, INC. | $95.90 | 2021 | |
| Celgene Corporation | $83.72 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $76.75 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $74.18 | 2021-2024 | |
| Allergan, INC. | $72.32 | 2019-2022 | |
| Lilly USA, LLC | $64.32 | 2024 | Amyvid, Emgality |
| Teva Pharmaceuticals USA, INC. | $59.07 | 2021-2024 | Austedo Xr |
| Tg Therapeutics, INC. | $45.02 | 2025 | |
| Ge Healthcare | $42.35 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $38.43 | 2022 | |
| Arbor Pharmaceuticals, INC. | $32.76 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $28.84 | 2021 | |
| Hospira, INC. | $28.70 | 2024 | |
| Cycle Pharmaceuticals INC | $25.84 | 2024-2025 | Tascenso Odt |
| Grifols USA, LLC | $20.84 | 2025 | Xembify |
| Impel Pharmaceuticals INC. | $20.14 | 2022 | |
| Alexion Pharmaceuticals, INC. | $18.46 | 2021 | |
| Mdd US Operations, LLC | $18.02 | 2024 | Gocovri |
| Neurocrine Biosciences, INC. | $16.83 | 2022 | |
| Boston Scientific Corporation | $16.45 | 2023 | Vercise |
| E.R. Squibb & Sons, L.L.C. | $14.61 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.02 | 2024 | Eohilia |
| Idorsia Pharmaceuticals US INC | $13.55 | 2023 | Quviviq |
| Biodelivery Sciences International, INC. | $13.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Greg Thaera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.